The Continual Search for Ideal Biomarkers for Mesothelioma: the Hurdles

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2013 Jul 5

PMID 23825777

Citations 3

Authors

Fraser J Brims

Y C Gary Lee

Jenette Creaney

Affiliations

Soon will be listed here.

Citing Articles

Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.

Dongel I, Akbas A, Benli I, Bayram M Turk Gogus Kalp Damar Cerrahisi Derg. 2020; 27(3):374-380.

PMID: 32082887 PMC: 7021410. DOI: 10.5606/tgkdc.dergisi.2019.17557.

Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.

Rouka E, Vavougios G, Solenov E, Gourgoulianis K, Hatzoglou C, Zarogiannis S Front Physiol. 2017; 8:156.

PMID: 28377727 PMC: 5359316. DOI: 10.3389/fphys.2017.00156.

Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Bayram M, Dongel I, Akbas A, Benli I, Akkoyunlu M, Bakan N Lung. 2013; 192(1):197-203.

PMID: 24170217 DOI: 10.1007/s00408-013-9526-9.

References

. Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol. 2013; 9(1):29-39. DOI: 10.1111/ajco.12062. View

Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W . Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010; 28(20):3316-22. DOI: 10.1200/JCO.2009.26.9944. View

Pass H, Lott D, Lonardo F, Harbut M, Liu Z, Tang N . Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005; 353(15):1564-73. DOI: 10.1056/NEJMoa051185. View

Le G, Takahashi K, Park E, Delgermaa V, Oak C, Qureshi A . Asbestos use and asbestos-related diseases in Asia: past, present and future. Respirology. 2011; 16(5):767-75. DOI: 10.1111/j.1440-1843.2011.01975.x. View

Davies H, Nicholson J, Rahman N, Wilkinson E, Davies R, Gary Lee Y . Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg. 2010; 38(4):472-7. DOI: 10.1016/j.ejcts.2010.01.057. View

Muminova Z, Strong T, Shaw D . Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer. 2004; 4:19. PMC: 420467. DOI: 10.1186/1471-2407-4-19. View

Mori T, Tajima K, Hirama M, Sato T, Kido K, Iwakami S . The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J Thorac Dis. 2013; 5(2):145-8. PMC: 3621927. DOI: 10.3978/j.issn.2072-1439.2013.03.03. View

Hollevoet K, Reitsma J, Creaney J, Grigoriu B, Robinson B, Scherpereel A . Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012; 30(13):1541-9. PMC: 3383122. DOI: 10.1200/JCO.2011.39.6671. View

Yamaguchi N, Hattori K, Kojima T, Imai N, Ochi N . A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994; 269(2):805-8. View

10.

Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P . Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 2011; 6(11):1930-7. DOI: 10.1097/JTO.0b013e3182272294. View

11.

Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M . Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006; 97(9):928-32. PMC: 11158852. DOI: 10.1111/j.1349-7006.2006.00246.x. View

12.

Onda M, Nagata S, Ho M, Bera T, Hassan R, Alexander R . Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res. 2006; 12(14 Pt 1):4225-31. DOI: 10.1158/1078-0432.CCR-06-0472. View

13.

Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De Vuyst P . Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med. 2010; 181(6):620-5. DOI: 10.1164/rccm.200907-1020OC. View

14.

Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O . Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun. 2000; 275(1):134-40. DOI: 10.1006/bbrc.2000.3280. View

15.

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View

16.

Davies H, Sadler R, Bielsa S, Maskell N, Rahman N, Davies R . Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med. 2009; 180(5):437-44. DOI: 10.1164/rccm.200811-1729OC. View

17.

Grigoriu B, Chahine B, Vachani A, Gey T, Conti M, Sterman D . Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med. 2009; 179(10):950-4. DOI: 10.1164/rccm.200807-1125OC. View

18.

Pass H, Levin S, Harbut M, Melamed J, Chiriboga L, Donington J . Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012; 367(15):1417-27. PMC: 3761217. DOI: 10.1056/NEJMoa1115050. View

19.

Creaney J, Francis R, Dick I, Musk A, Robinson B, Byrne M . Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2010; 17(5):1181-9. DOI: 10.1158/1078-0432.CCR-10-1929. View

20.

Ostroff R, Mehan M, Stewart A, Ayers D, Brody E, Williams S . Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 2012; 7(10):e46091. PMC: 3463527. DOI: 10.1371/journal.pone.0046091. View